בינוקריט 40000 יחבל  1 מל Իսրայել - եբրայերեն - Ministry of Health

בינוקריט 40000 יחבל 1 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 40000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

נורווסק 5 מג טבליות Իսրայել - եբրայերեն - Ministry of Health

נורווסק 5 מג טבליות

pfizer pfe pharmaceuticals israel ltd - amlodipine as besylate - טבליה - amlodipine as besylate 5 mg - amlodipine - amlodipine - mild to moderate hypertension. vasospastic angina ( prinzmetal's or variant angina). chronic stable angina.

נורווסק 10 מג טבליות Իսրայել - եբրայերեն - Ministry of Health

נורווסק 10 מג טבליות

pfizer pfe pharmaceuticals israel ltd - amlodipine as besylate - טבליה - amlodipine as besylate 10 mg - amlodipine - amlodipine - mild to moderate hypertension. vasospastic angina ( prinzmetal's or variant angina). chronic stable angina.

אמלו 5 Իսրայել - եբրայերեն - Ministry of Health

אמלו 5

unipharm ltd, israel - amlodipine as maleate - טבליה - amlodipine as maleate 5 mg - amlodipine - amlodipine - mild to moderate hypertension. vasospastic angina (prinzmetal's or variant angina). chronic stable angina.

אמלו 10 Իսրայել - եբրայերեն - Ministry of Health

אמלו 10

unipharm ltd, israel - amlodipine as maleate - טבליה - amlodipine as maleate 10 mg - amlodipine - amlodipine - mild to moderate hypertension. vasospastic angina (prinzmetal's or variant angina). chronic stable angina.

קדואט ® 5/10 Իսրայել - եբրայերեն - Ministry of Health

קדואט ® 5/10

pfizer pharmaceuticals israel ltd - amlodipine as besylate 5 mg; atorvastatin as calcium 10 mg - film coated tablets - amlodipine - caduet (amlodipine and atorvastatin ) is indicated in patients for whom treatment with both amlodipine and atorvastatin is apptopriate. amlodipine: - hypertension - chronic stable angina - vasospastic angina (prinzmetal's or variant angina). atorvastatin : - prevention of cardiovascular disease - heterozygous familial and nonfamilial hypercholesterolemia - elevated serum tg levels - primary dysbetalipoproteinemia - homozygous familial hypercholesterolemia - pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient.

קדואט ® 5/20 Իսրայել - եբրայերեն - Ministry of Health

קדואט ® 5/20

pfizer pharmaceuticals israel ltd - amlodipine as besylate 5 mg; atorvastatin as calcium 20 mg - film coated tablets - amlodipine - caduet (amlodipine and atorvastatin ) is indicated in patients for whom treatment with both amlodipine and atorvastatin is apptopriate. amlodipine: - hypertension - chronic stable angina - vasospastic angina (prinzmetal's or variant angina). atorvastatin : - prevention of cardiovascular disease - heterozygous familial and nonfamilial hypercholesterolemia - elevated serum tg levels - primary dysbetalipoproteinemia - homozygous familial hypercholesterolemia - pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient.

קדואט ® 5/40 Իսրայել - եբրայերեն - Ministry of Health

קדואט ® 5/40

pfizer pharmaceuticals israel ltd - amlodipine as besylate 5 mg; atorvastatin as calcium 40 mg - film coated tablets - amlodipine - caduet (amlodipine and atorvastatin ) is indicated in patients for whom treatment with both amlodipine and atorvastatin is apptopriate. amlodipine: - hypertension - chronic stable angina - vasospastic angina (prinzmetal's or variant angina). atorvastatin : - prevention of cardiovascular disease - heterozygous familial and nonfamilial hypercholesterolemia - elevated serum tg levels - primary dysbetalipoproteinemia - homozygous familial hypercholesterolemia - pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient.

קדואט ® 5/80 Իսրայել - եբրայերեն - Ministry of Health

קדואט ® 5/80

pfizer pharmaceuticals israel ltd - amlodipine as besylate 5 mg; atorvastatin as calcium 80 mg - film coated tablets - amlodipine - caduet (amlodipine and atorvastatin ) is indicated in patients for whom treatment with both amlodipine and atorvastatin is apptopriate. amlodipine: - hypertension - chronic stable angina - vasospastic angina (prinzmetal's or variant angina). atorvastatin : - prevention of cardiovascular disease - heterozygous familial and nonfamilial hypercholesterolemia - elevated serum tg levels - primary dysbetalipoproteinemia - homozygous familial hypercholesterolemia - pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient.

קדואט ® 10/10 Իսրայել - եբրայերեն - Ministry of Health

קדואט ® 10/10

pfizer pharmaceuticals israel ltd - amlodipine as besylate 10 mg; atorvastatin as calcium 10 mg - film coated tablets - amlodipine - caduet (amlodipine and atorvastatin ) is indicated in patients for whom treatment with both amlodipine and atorvastatin is apptopriate. amlodipine: - hypertension - chronic stable angina - vasospastic angina (prinzmetal's or variant angina). atorvastatin : - prevention of cardiovascular disease - heterozygous familial and nonfamilial hypercholesterolemia - elevated serum tg levels - primary dysbetalipoproteinemia - homozygous familial hypercholesterolemia - pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient.